Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Steven E Marx"'
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 7, Pp 1849-1860 (2023)
Abstract Introduction The EXPEDITION-8 clinical trial has demonstrated that treatment-naïve patients with compensated cirrhosis (TN/CC) of HCV genotypes 1–6 can achieve a 98% intent-to-treat sustained virologic response rate 12 weeks post-treatmen
Externí odkaz:
https://doaj.org/article/e225705152f14a45bfdfabaca715d207
Autor:
Emmanuel, Thomas, Wei-Han, Cheng, Douglas E, Dylla, Steven E, Marx, Jana, Carabino, Qingqing, Xu
Publikováno v:
Infectious Diseases and Therapy. 11:451-462
Progress towards achieving hepatitis C virus (HCV) elimination in Florida has been hampered by barriers to screening, linkage to care, and treatment. This study aims to describe the HCV care cascade and patient characteristics in Florida.This analysi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cd5c9d1589b9a6928de382ddbfc7787
https://doi.org/10.1007/s40121-021-00578-5
https://doi.org/10.1007/s40121-021-00578-5
Autor:
Katia E. Valdez, Marjan Javanbakht, Kori Keith, Roxanne Archer, John Z. Deng, Steven E. Marx, Arina Kuznetsova, Douglas E. Dylla, Jeffrey D. Klausner
Publikováno v:
Frontiers in Gastroenterology. 1
BackgroundThe objective of this study was to examine differences in healthcare utilization among patients receiving eight vs. 12-weeks of treatment for infection with the Hepatitis C Virus (HCV).MethodsWe conducted a retrospective cohort study among
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d852eb2fd880153aac2b402c900f91da
https://doi.org/10.3389/fgstr.2022.988971
https://doi.org/10.3389/fgstr.2022.988971
Autor:
Pietro Lampertico, Heiner Wedemeyer, Marcello Persico, Fiona Marra, Kristina Lohmann, Steven L. Flamm, Mark Bondin, Steven E Marx, Stephen T. Barclay, Zhen Zhen Zhang, Pamela S. Belperio, Stefan Mauss
Publikováno v:
Advances in Therapy
ADVANCES IN THERAPY
ADVANCES IN THERAPY
Introduction: More than 70 million people are estimated to be infected with hepatitis C virus globally. Glecaprevir/pibrentasvir is a widely used treatment and has recently been approved for an 8-week regimen for treatment-naïve patients with compen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84815f3c681f3412b431006e0fa7968e
http://europepmc.org/articles/PMC7547986
http://europepmc.org/articles/PMC7547986
Autor:
Steven L. Flamm, Nicole Wick, Bruce R. Bacon, Jens Kort, Naoky Tsai, Michael P. Curry, Douglas E. Dylla, John Strezewski, Steven E Marx
Publikováno v:
Advances in Therapy
Introduction Glecaprevir/pibrentasvir (G/P) was approved on 26 September 2019 by the US Food and Drug Administration for 8-week duration in treatment-naïve (TN) hepatitis C virus (HCV)-infected patients with compensated cirrhosis (CC). Evidence from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f575fa1f62501e9eebf03365e1242daa
https://doi.org/10.1007/s12325-020-01301-5
https://doi.org/10.1007/s12325-020-01301-5
Autor:
Yuri Sanchez Gonzalez, Wei-Han Cheng, Steven E Marx, John Strezewski, Nancy Reau, Mark S. Sulkowski
Publikováno v:
Advances in Therapy
Introduction Although hepatitis C virus (HCV) infection remains a major clinical, economic, and societal burden, the development of curative antiviral therapy may accelerate the path toward elimination. This analysis assessed the progress of United S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8103583fee945e50ca70ab7f4aa2acb
https://pubmed.ncbi.nlm.nih.gov/33145648
https://pubmed.ncbi.nlm.nih.gov/33145648
Publikováno v:
Advances in Therapy. 35:1087-1102
Chronic infection with hepatitis C virus (HCV) is a leading cause of liver disease and infectious disease deaths. While recent and emerging treatment options for HCV patients have enabled higher rates of sustained virologic response (SVR), the demogr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25548c507b040d499c42d0bb1e844cfa
https://doi.org/10.1007/s12325-018-0721-1
https://doi.org/10.1007/s12325-018-0721-1
Autor:
Pietro Lampertico, Pamela S. Belperio, Fiona Marra, Steven E Marx, Kristina Lohmann, Stephen T. Barclay, Stefan Mauss, Mark Bondin, Heiner Wedemeyer, Zhen Zhen Zhang, Steven L. Flamm, Marcello Persico
Publikováno v:
Advances in Therapy
More than 70 million people are estimated to be infected with hepatitis C virus globally. Glecaprevir/pibrentasvir is a widely used treatment and has recently been approved for an 8-week regimen for treatment-naïve patients with compensated cirrhosi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4732b17186dcaa2d7fa1380b8215a55e
https://doi.org/10.1007/s12325-020-01482-z
https://doi.org/10.1007/s12325-020-01482-z
Publikováno v:
Gastroenterology. 158:S-1274
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c10ff8b706de6cc3297d3c290fe0a56
https://doi.org/10.1016/s0016-5085(20)33848-8
https://doi.org/10.1016/s0016-5085(20)33848-8
Publikováno v:
Advances in Therapy
Introduction Clinical trials have demonstrated the efficacy of all-oral direct-acting antiviral (DAA) regimens in the treatment of patients infected with hepatitis C virus (HCV). This study assessed real-world effectiveness of two recently approved r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d64a30fa776e95a75654a64d6c7d05b7
https://doi.org/10.1007/s12325-015-0258-5
https://doi.org/10.1007/s12325-015-0258-5